ClinicalTrials.gg
CompletedNCT02886884ACESOUpdated May 11, 2022Results posted

Allogeneic Mesenchymal Human Stem Cells Infusion Therapy for Endothelial DySfunctiOn in Diabetic Subjects

A Phase 1/2 interventional study of 20 million Allogeneic Mesenchymal Human Stem Cells and 100 million Allogeneic Mesenchymal Human Stem Cells in Diabetes Mellitus, Type 2, sponsored by Joshua M Hare. Completed at 1 site in United States. Open to participants aged 21 Years to 90 Years. Per ClinicalTrials.gov, last updated 2022-05-11.

Sponsored by Joshua M Hare · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
21 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 3,308 studies in Diabetes Mellitus, Type 2 with a site in United States — 345 open to participants now, 479 under way, 51 of them phase 3. Diabetes Mellitus, Type 2 · United States.

Enrollment
2,608th of 2,961
16 · median 90
Started
2017
with 145 others
Phase 1/2
41 of 3,308
4 open now
Registered
1,860th of 3,308
by date

Among the 3,308 studies in Diabetes Mellitus, Type 2 with a site in United States, this one is the 2,608th largest by enrollment of the 2,961 interventional ones that give a count, is one of 146 that started in 2017, is one of 41 in phase 1/2, and was the 1,860th registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

345 of the 3,308 studies in Diabetes Mellitus, Type 2 with a site in United States are open now. Recruiting first, the newest first:

340 more — sign in →

All 345 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 21 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,308 studies in Diabetes Mellitus, Type 2 with a site in United States, or all of them as a file.
02

Study summary

This is a 16 subject trial to demonstrate the safety of allogeneic hMSCs administered via infusion therapy for diabetic subjects with endothelial dysfunction.

03

Conditions studied

  • Diabetes Mellitus, Type 2

Keywords

  • Diabetes
  • Endothelial dysfunction
  • Stem cells
04

Who can participate

Ages eligible
21 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be ≥ 21 and \< 90 (inclusive) years of age.
  • Provide written .
  • Have endothelial dysfunction defined by impaired flow-mediated vasodilation (FMD \<7%).
  • Have an > 45% by gated blood pool scan, two- dimensional echocardiogram, cardiac MRI, cardiac CT or left ventriculogram within the prior 3 months.
  • Have Diabetes mellitus type 2 documented by adult type 1 component () > 7% or on medical therapy for diabetes.
  • Females of must use two forms of for the duration of the study. Female subjects must undergo a blood or urine pregnancy test at screening and within 36 hours prior to infusion.

Exclusion criteria

Exclusion Criteria:

In order to participate in this study, a subject Must Not:

  • Be younger than 21 years or older than 90 years of age.
  • Have a baseline \<35 ml/min 1.73m\^2 estimated using the Modification of Diet in renal disease (MDRD) formula.
  • Have an \<45% by gated blood pool scan, two-dimensional echocardiogram, cardiac MRI, cardiac CT or left ventriculogram within the past year, as documented by medical history.
  • Have poorly controlled blood glucose levels with > 8.5%.
  • Have a history of proliferative retinopathy or severe neuropathy requiring medical treatment.
  • Have a hematologic abnormality as evidenced by hematocrit \< 25%, white blood cell \< 2,500/ul or values \< 100,000/ul without another explanation.
  • Have liver dysfunction, as evidenced by enzymes ( and ALT) greater than three times the .
  • Have a bleeding diathesis or coagulopathy ( > 1.3), cannot be withdrawn from anticoagulation therapy, or will refuse blood transfusions.
  • Have Lymphadenectomy or Lymph node dissection in the right arm.
  • Be an organ transplant recipient or have a history of organ or cell transplant rejection.
  • Have a clinical history of within the past 5 years (i.e., subjects with prior malignancy must be disease free for 5 years), except curatively- treated basal cell or squamous cell carcinoma, or cervical carcinoma.
  • Have a condition that limits lifespan to \< 1 year.
  • Have a history of drug or alcohol abuse within the past 24 months.
  • Be on chronic therapy with medication, such as or Tumor Necrosis Factor - alpha (TNFα) antagonists.
  • Be serum positive for , Syphilis - VDRL (Confirmation with FTA-ABS if needed (Syphilis)), surface antigen or viremic .
  • Be currently participating (or participated within the previous 30 days) in an therapeutic or device trial.
  • Be pregnant, nursing, or of while not practicing effective methods.
  • Any other condition that in the judgment of the Investigator would be a to enrollment or follow-up.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Pilot Phase 20 million allogeneic hMSCs

    Participants in this group will receive one peripheral intravenous infusion of 20 million allogeneic Mesenchymal Human Stem Cells (hMSCs)

    Drug: 20 million Allogeneic Mesenchymal Human Stem Cells

  • Experimental
    Pilot Phase 100 million hMSCs

    Participants in this group will receive one peripheral intravenous infusion of 100 million allogeneic Mesenchymal Human Stem Cells (hMSCs)

    Drug: 100 million Allogeneic Mesenchymal Human Stem Cells

  • Experimental
    Randomized Phase 20 million allogeneic hMSCs

    Participants in this group will receive one peripheral intravenous infusion of 20 million allogeneic Mesenchymal Human Stem Cells (hMSCs)

    Drug: 20 million Allogeneic Mesenchymal Human Stem Cells

  • Experimental
    Randomized Phase 100 million allogeneic hMSCs

    Participants in this group will receive one peripheral intravenous infusion of 100 million allogeneic Mesenchymal Human Stem Cells (hMSCs)

    Drug: 100 million Allogeneic Mesenchymal Human Stem Cells

Interventions

  • DrugStem CellStudies of Stem CellStem Cell pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    1 single intravenous infusion

    Also known as: allo-hMSCs, stem cells

  • DrugStem CellStudies of Stem CellStem Cell pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    1 single intravenous infusion

    Also known as: allo-hMSCs, stem cells

06

What researchers measure

Primary outcomes

  1. Number of Treatment Emergent Serious Adverse Events (TE-SAEs)

    TE-SAEs as evaluated by the investigator which may include but not limited to: death, non-fatal pulmonary embolism, stroke, hospitalization for worsening dyspnea and clinically significant laboratory test abnormalities.

    Time frame: Up to one month (post infusion)

Secondary outcomes

  1. EPC-CFU Levels

    Endothelial Progenitor Cell Colony Forming Units (EPC-CFU) will be assessed from blood samples

    Time frame: At Baseline, Day 3, Day 7, Day 14, Day 28, Day 90, Day 180, Day 365

  2. CRP Marker Levels

    C-Reactive Protein (CRP) levels will be assessed from blood samples and reported in mg/L

    Time frame: At Baseline, Day 3, Day 7, Day 14, Day 28, Day 90, Day 180, Day 365

  3. Circulating Angiogenic Factor Levels

    Circulating Angiogenic Factor levels including Vascular Endothelial Growth Factor (VEGF), Stem Cell Factor (SCF) and Stromal Cell-Derived Factor 1 (SDF-1) will be assessed from blood samples and reported in ng/mL

    Time frame: At Baseline, Day 3, Day 7, Day 14, Day 28, Day 90, Day 180, Day 365

  4. Flow Mediated Diameter Percentage (FMD%)

    FMD will be assessed using brachial artery ultrasound

    Time frame: At Baseline, Day 3, Day 7, Day 14, Day 28, Day 90, Day 180, Day 365

  5. Circulating Inflammatory Marker Levels

    Circulating inflammatory marker levels including Interleukin (IL) -1 and IL-6 will be assessed from blood samples and reported in pg/mL

    Time frame: At Baseline, Day 3, Day 7, Day 14, Day 28, Day 90, Day 180, Day 365

  6. Tumor Necrosis Factor (TNF) Alpha Levels

    Measured from blood samples (pg/mL)

    Time frame: At Baseline, Day 3, Day 7, Day 14, Day 28, Day 90, Day 180, Day 365

07

Results

Posted May 11, 2022

Participant flow

Treatment
Participant flow — Treatment
MilestonePilot Phase 20 Million Allogeneic hMSCsPilot Phase 100 Million hMSCsRandomized Phase 20 Million Allogeneic hMSCsRandomized Phase 100 Million Allogeneic hMSCs
Started3355
Completed3355
Not completed0000
Follow-up
Participant flow — Follow-up
MilestonePilot Phase 20 Million Allogeneic hMSCsPilot Phase 100 Million hMSCsRandomized Phase 20 Million Allogeneic hMSCsRandomized Phase 100 Million Allogeneic hMSCs
Started3355
Completed3354
Not completed0001
Withdrew: Withdrawal by subject0001

Outcome measures

PrimaryNumber of Treatment Emergent Serious Adverse Events (TE-SAEs)

TE-SAEs as evaluated by the investigator which may include but not limited to: death, non-fatal pulmonary embolism, stroke, hospitalization for worsening dyspnea and clinically significant laboratory test abnormalities.

Time frame:
Up to one month (post infusion)
Reported as:
Number · Treatment Emergent SAE
Number of Treatment Emergent Serious Adverse Events (TE-SAEs)
Treatment Emergent SAEPilot Phase 20 Million Allogeneic hMSCsPilot Phase 100 Million hMSCsRandomized Phase 20 Million Allogeneic hMSCsRandomized Phase 100 Million Allogeneic hMSCs
Number of Treatment Emergent Serious Adverse Events (TE-SAEs)0000
SecondaryEPC-CFU Levels

Endothelial Progenitor Cell Colony Forming Units (EPC-CFU) will be assessed from blood samples

Time frame:
At Baseline, Day 3, Day 7, Day 14, Day 28, Day 90, Day 180, Day 365
Reported as:
Mean · Colony forming units
EPC-CFU Levels
Colony forming unitsPilot Phase 20 Million Allogeneic hMSCsPilot Phase 100 Million hMSCsRandomized Phase 20 Million Allogeneic hMSCsRandomized Phase 100 Million Allogeneic hMSCs
Baseline2.06 ± 1.353.16 ± 1.922.37 ± 2.601.93 ± 1.38
Day 33.39 ± 3.315.50 ± 3.014.37 ± 3.202.80 ± 1.72
Day 79.28 ± 14.216.94 ± 8.676.07 ± 3.515.53 ± 4.78
Day 146.11 ± 8.7419.72 ± 17.498.23 ± 4.0711.70 ± 11.58
Day 287.83 ± 5.2021.83 ± 2.962.50 ± 0.966.70 ± 8.27
Day 909.17 ± 8.7214.17 ± 2.321.90 ± 2.506.50 ± 8.16
Day 1808.39 ± 7.0714.33 ± 3.122.45 ± 3.414.50 ± 6.46
Day 3656.89 ± 4.688.83 ± 3.911.04 ± 0.632.94 ± 4.25
SecondaryCRP Marker Levels

C-Reactive Protein (CRP) levels will be assessed from blood samples and reported in mg/L

Time frame:
At Baseline, Day 3, Day 7, Day 14, Day 28, Day 90, Day 180, Day 365

No measurements were reported for this outcome.

SecondaryCirculating Angiogenic Factor Levels

Circulating Angiogenic Factor levels including Vascular Endothelial Growth Factor (VEGF), Stem Cell Factor (SCF) and Stromal Cell-Derived Factor 1 (SDF-1) will be assessed from blood samples and reported in ng/mL

Time frame:
At Baseline, Day 3, Day 7, Day 14, Day 28, Day 90, Day 180, Day 365

No measurements were reported for this outcome.

SecondaryFlow Mediated Diameter Percentage (FMD%)

FMD will be assessed using brachial artery ultrasound

Time frame:
At Baseline, Day 3, Day 7, Day 14, Day 28, Day 90, Day 180, Day 365
Reported as:
Mean · Percent dilation of brachial artery
Flow Mediated Diameter Percentage (FMD%)
Percent dilation of brachial arteryPilot Phase 20 Million Allogeneic hMSCsPilot Phase 100 Million hMSCsRandomized Phase 20 Million Allogeneic hMSCsRandomized Phase 100 Million Allogeneic hMSCs
Baseline2.55 ± 1.114.33 ± 2.614.55 ± 1.173.11 ± 1.92
Day 32.86 ± 1.964.76 ± 1.465.19 ± 1.334.99 ± 1.98
Day 72.97 ± 1.615.06 ± 3.704.80 ± 0.985.35 ± 2.45
Day 142.62 ± 0.535.18 ± 3.785.10 ± 1.554.94 ± 1.50
Day 282.33 ± 1.354.45 ± 3.945.67 ± 2.636.19 ± 2.53
Day 901.26 ± 0.504.78 ± 2.495.65 ± 2.895.34 ± 2.44
Day 1802.90 ± 1.744.32 ± 2.475.78 ± 3.114.04 ± 1.84
Day 3651.81 ± 0.244.14 ± 0.383.88 ± 1.613.65 ± 1.75
SecondaryCirculating Inflammatory Marker Levels

Circulating inflammatory marker levels including Interleukin (IL) -1 and IL-6 will be assessed from blood samples and reported in pg/mL

Time frame:
At Baseline, Day 3, Day 7, Day 14, Day 28, Day 90, Day 180, Day 365

No measurements were reported for this outcome.

SecondaryTumor Necrosis Factor (TNF) Alpha Levels

Measured from blood samples (pg/mL)

Time frame:
At Baseline, Day 3, Day 7, Day 14, Day 28, Day 90, Day 180, Day 365
Reported as:
Mean · pg/mL
Tumor Necrosis Factor (TNF) Alpha Levels
pg/mLPilot Phase 20 Million Allogeneic hMSCsPilot Phase 100 Million hMSCsRandomized Phase 20 Million Allogeneic hMSCsRandomized Phase 100 Million Allogeneic hMSCs
Baseline0.79 ± 0.130.80 ± 0.190.85 ± 0.210.80 ± 0.12
Day 30.74 ± 0.040.86 ± 0.331.01 ± 0.240.81 ± 0.15
Day 70.77 ± 0.030.74 ± 0.090.90 ± 0.451.09 ± 0.55
Day 140.80 ± 0.041.01 ± 0.200.93 ± 0.410.90 ± 0.33
Day 280.69 ± 0.200.84 ± 0.170.84 ± 0.310.82 ± 0.19
Day 900.68 ± 0.150.81 ± 0.130.83 ± 0.100.71 ± 0.12
Day 18017.10 ± NA0.98 ± 0.510.79 ± 0.250.76 ± 0.10
Day 3650.83 ± 0.230.95 ± 0.320.76 ± 0.080.81 ± 0.23

Adverse events

Collected over 12 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pilot Phase 20 Million Allogeneic hMSCs0/3 (0%)1/3 (33.3%)2/3 (66.7%)
Pilot Phase 100 Million hMSCs0/3 (0%)1/3 (33.3%)2/3 (66.7%)
Randomized Phase 20 Million Allogeneic hMSCs0/5 (0%)0/5 (0%)5/5 (100%)
Randomized Phase 100 Million Allogeneic hMSCs0/5 (0%)1/5 (20%)5/5 (100%)
Most frequent serious events
Most frequent serious events
EventPilot Phase 20 Million Allogeneic hMSCsPilot Phase 100 Million hMSCsRandomized Phase 20 Million Allogeneic hMSCsRandomized Phase 100 Million Allogeneic hMSCs
Chest PainCardiac disorders1/30/30/50/5
AdenocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/31/30/50/5
Gastrointestinal Stromal TumorNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/30/30/51/5
Abdominal Surgical Site InfectionInfections and infestations0/30/30/51/5
Most frequent other events
Showing 10 of 32
Most frequent other events
EventPilot Phase 20 Million Allogeneic hMSCsPilot Phase 100 Million hMSCsRandomized Phase 20 Million Allogeneic hMSCsRandomized Phase 100 Million Allogeneic hMSCs
Poor Diabetes ControlMetabolism and nutrition disorders1/30/32/54/5
Upper Respiratory InfectionInfections and infestations0/30/32/50/5
FallInjury, poisoning and procedural complications0/30/32/50/5
Chest PainCardiac disorders0/31/30/50/5
Recurrence of Gastrointestinal bleedGastrointestinal disorders1/30/30/50/5
Allergic Reaction to Flu shotImmune system disorders0/31/30/50/5
Viral IllnessInfections and infestations0/31/30/50/5
HypercalcemiaMetabolism and nutrition disorders0/31/30/50/5
Abnormal UrinalysisRenal and urinary disorders0/31/30/50/5
ProteinureaRenal and urinary disorders0/31/30/51/5

Baseline characteristics

Age, Continuous
Age, Continuous(years)Pilot Phase 20 Million Allogeneic hMSCsPilot Phase 100 Million hMSCsRandomized Phase 20 Million Allogeneic hMSCsRandomized Phase 100 Million Allogeneic hMSCsTotal
Mean69.3 ± 13.669.3 ± 6.759.8 ± 13.762.0 ± 8.164.1 ± 10.8
Sex: Female, Male
Sex: Female, Male(Participants)Pilot Phase 20 Million Allogeneic hMSCsPilot Phase 100 Million hMSCsRandomized Phase 20 Million Allogeneic hMSCsRandomized Phase 100 Million Allogeneic hMSCsTotal
Female00325
Male332311
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Pilot Phase 20 Million Allogeneic hMSCsPilot Phase 100 Million hMSCsRandomized Phase 20 Million Allogeneic hMSCsRandomized Phase 100 Million Allogeneic hMSCsTotal
Hispanic or Latino00325
Not Hispanic or Latino332311
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Pilot Phase 20 Million Allogeneic hMSCsPilot Phase 100 Million hMSCsRandomized Phase 20 Million Allogeneic hMSCsRandomized Phase 100 Million Allogeneic hMSCsTotal
American Indian or Alaska Native00000
Asian10001
Native Hawaiian or Other Pacific Islander00000
Black or African American00123
White234312
More than one race00000
Unknown or Not Reported00000
08

Study locations

1 site
  • University of Miami Miller School of Medicine
    Miami, Florida 33136, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2017 to primary completion in Aug 2019, 22 months.

Results were first posted in May 2022, 2 years 8 months after primary completion.

Of 41 phase 1/2 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 71. This study's 22 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 29, 2016
First posted
Sep 1, 2016
StartActual
Oct 20, 2017
Primary completionActual
Aug 26, 2019
CompletionActual
Sep 3, 2020
Results first posted
May 11, 2022
Last update
May 11, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 11, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02886884
Lead sponsor
Joshua M Hare
Responsible party
Joshua M Hare (Sponsor - Investigator, University of Miami) — Sponsor-investigator
First posted
Sep 1, 2016
Start date
Oct 20, 2017
Primary completion
Aug 26, 2019
Completion
Sep 3, 2020
Results posted
May 11, 2022
Last update
May 11, 2022

Study contacts

Joshua M Hare, MD
principal investigator · ISCI / University of Miami Miller School of Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Stem Cell

Start the discussion